CAR T-cell therapy is a popular immunotherapy used to target cancers, specifically hematological malignancies such as B-cell lymphomas and acute lymphoblastic leukemia, Figure (4). The procedure centers around extracting a patient's T cells, genetically modifying them, and then readministering the altered T cells . The modifications will generate receptors on the surface that recognize antigenic proteins on the cancer cell surface (6). This enables targeting cancer cells while reducing the risk of harming healthy cells . Since its emergence, CAR T-cell therapy has shown remarkable success in patients resistant to conventional treatments due to its unique personalization and recognizing features (4). Once initially administered, the modified T cells will increase, allowing for continued surveillance of cancer cells . However, this therapy has potential risks, including cytokine release syndrome (CRS), a condition characterized by an overactive immune system, and neurotoxicity, where an adverse functional or structural change occurs in the nervous system . Despite this, the treatment proves to be a significant advancement, offering hope for patients diagnosed with otherwise refractory cancer . Researchers hope to expand upon the efficiency of this treatment and, eventually, work towards its use as a treatment for solid tumors. Interleukin-13 receptor subunit alpha-2 (IL-13Rα2) is a protein overexpressed on the surface of malignant cells in many cases of GBM, making it a promising target for cancer therapies . IL-13Rα2 is part of the receptor complex for the cytokine IL-13 but is distinct from the IL-13Rα1 protein as it binds IL-13 with high affinity but does not initiate healthy immune signaling pathways . In fact, IL-13Rα2 is considered a decoy receptor (a decoy receptor binds to a ligand without triggering a response, blocking the ligand from activating its normal signaling receptor) that regulates IL-13 activity to potentially contribute to the immunosuppressive tumor environment that promotes glioblastoma growth; because of this and its overexpression in glioblastoma cells, the IL-13Rα2 protein presents as a significant target for therapeutic interventions . As the exploration of multiple approaches, including monoclonal antibodies, fusion proteins, and CAR T-cell therapies specific to target IL-13Rα2, is underway, these therapies aim to increase specificity and efficiency while minimizing damage to healthy brain tissue . Research on targeting IL-13Rα2 presents results that support the promise of reducing tumor growth and improving survival in preclinical models of glioblastoma . Ongoing clinical trials testing IL-13Rα2-targeted therapies in patients with GBM aim to develop new effective treatments for this aggressive, treatment-resistant brain cancer .